Skip to main content

Advertisement

Table 4 Mean PT and aPTT values by treatment group on day 7 and at treatment completion

From: A randomized, open-label trial of edoxaban in Japanese patients with severe renal impairment undergoing lower-limb orthopedic surgery

    Day 7 Completion day of treatment
Parameter Treatment group Pre dose 1 to 3 h 4 to 8 h Pre dose 1 to 3 h 4 to 8 h
PT (s) MiRI n Edoxaban 30 mg 29 29 29 30 29 28
  Mean (SD) CLCR ≥50 to <80 mL/min 13.7 (1.1) 16.8 (3.6) 17.4 (1.8) 13.6 (1.0) 17.6 (3.4) 17.5 (2.1)
  SRI n Edoxaban 15 mg (total) 27 27 27 26 25 26
  Mean (SD) CLCR ≥15 to <30 mL/min 14.0 (1.2) 16.1 (2.1) 16.2 (1.4) 14.1 (1.1) 15.9 (1.9) 16.5 (1.6)
   Edoxaban 15 mg 7 7 7 6 7 7
   CLCR ≥15 to <20 mL/min 14.8 (1.3) 16.9 (2.1) 16.9 (1.1) 15.0 (1.5) 16.6 (2.3) 17.1 (2.5)
   Edoxaban 15 mg 20 20 20 20 18 19
   CLCR ≥20 to <30 mL/min 13.8 (1.0) 15.8 (2.1) 15.9 (1.4) 13.9 (0.9) 15.6 (1.8) 16.3 (1.2)
   Fondaparinux 20 20 20 19 17 18
   CLCR ≥20 to <30 mL/min 13.5 (0.9) 13.6 (0.9) 13.5 (0.9) 13.7 (1.1) 13.7 (1.1) 13.6 (1.1)
aPTT (s) MiRI n Edoxaban 30 mg 29 29 29 30 29 28
  Mean (SD) CLCR ≥50 to <80 mL/min 32.2 (3.3) 37.7 (6.2) 38.9 (6.3) 31.7 (3.6) 39.3 (7.5) 39.8 (6.5)
  SRI n Edoxaban 15 mg (total) 27 27 27 26 25 26
  Mean (SD) CLCR ≥15 to <30 mL/min 31.6 (3.5) 35.7 (6.0) 36.1 (4.2) 31.0 (4.3) 34.0 (4.8) 35.6 (4.8)
   Edoxaban 15 mg 7 7 7 6 7 7
   CLCR ≥15 to <20 mL/min 32.7 (4.4) 36.6 (7.3) 36.2 (7.0) 31.1 (4.9) 34.2 (6.0) 34.7 (7.0)
   Edoxaban 15 mg 20 20 20 20 18 19
   CLCR ≥20 to <30 mL/min 31.2 (3.1) 35.4 (5.7) 36.1 (3.0) 31.0 (4.2) 34.0 (4.4) 36.0 (3.8)
   Fondaparinux 20 20 20 19 17 18
   CLCR ≥20 to <30 mL/min 32.5 (4.4) 32.6 (4.5) 32.3 (5.0) 32.9 (3.9) 33.2 (5.8) 33.5 (4.7)
  1. aPTT = activated partial thromboplastin time; CLCR = creatinine clearance; MiRI = mild renal impairment; PT = prothrombin time; SD = standard deviation; SRI = severe renal impairment.